Loading clinical trials...
Loading clinical trials...
An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
UCB Pharma
NCT07171983 · Rheumatoid Arthritis
NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and more
NCT07558850 · Rheumatoid Arthritis, Dermatomyositis, and more
NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more
NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more
172
Palm Desert, California
185
Pasadena, California
170
Santa Maria, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions